Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Wegovy is a glucagon-like peptide-1 receptor agonist (also known as GLP-1 receptor agonist or GLP-1 RA), which bagged US Food and Drug Administrations approval as a treatment for obesity in June 2021
Clinical Results with Combination Therapy The SURPASS-COMBO trial demonstrated remarkable outcomes with CagriSema
Claims for GLP-1s Increased Four-Fold Between 2019 and 2024 In accordance with an increase in both the number of Medicare Part D enrollees using GLP-1s and spending on these products, the number of claims for GLP-1s increased four-fold between 2019 and 2024, from 4.8 million to 21.8 million, with claims doubling between 2022 and 2024 alone
doi: 10.3389/fimmu.2022.865267 11 ZhaoJWeiKChangCXuLJiangPGuoSet al
US$ 21.74
US$ 24.78
US$ 27.63
US$ 20.68
US$ 20.31
US$ 23.47
US$ 27.25
